Literature DB >> 18280273

The spleen--a potential source of new islets for transplantation?

Stuart A Robertson1, Autumn M Rowan-Hull, Paul R V Johnson.   

Abstract

BACKGROUND/
PURPOSE: Islet transplantation offers the potential to reverse diabetes soon after diagnosis and has achieved considerable success in adults. Its use in children has been limited by long-term immunosuppression requirements and donor pancreas shortages. An ideal alternative source of islets would be from autologous precursor cells. The aim of this study was to determine whether the spleen can produce insulin-producing cells (IPCs) in our established model of pancreatic development.
METHODS: Embryonic quail spleens (day 4.5) and chick pancreatic epithelium (day 4) were microdissected and recombined in a ratio of 1:1 (n = 12), 2:1 (n = 9) and 2:2 (n = 5). They were cultured for 7 days, sectioned, and analysed by fluorescent immunochemistry. Controls were performed to ensure clean separation.
RESULTS: Overall, 12 (46%) of 26 recombinants contained IPCs of splenic origin, occurring in 5 (42%) of 12 of the of 1 spleen-1 epithelium recombinants, 3 (33%) of 9 of the 2 spleen-1 epithelium recombinants, and 4 (80%) of 5 of the 2 spleen-2 epithelia recombinants. Controls were negative.
CONCLUSIONS: Preliminary results suggest developing avian spleens can differentiate into IPCs. Increased tissue mass enhanced the likelihood of this occurring. Mesenchyme-to-epithelia ratio did not influence this. The spleen could be an ideal autologous islet source for transplantation in children.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18280273     DOI: 10.1016/j.jpedsurg.2007.10.013

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  8 in total

Review 1.  Considerations for an Alternative Site of Islet Cell Transplantation.

Authors:  Poppy Addison; Karina Fatakhova; Horacio L Rodriguez Rilo
Journal:  J Diabetes Sci Technol       Date:  2019-08-09

Review 2.  Stem cells in the spleen: therapeutic potential for Sjogren's syndrome, type I diabetes, and other disorders.

Authors:  Denise L Faustman; Miriam Davis
Journal:  Int J Biochem Cell Biol       Date:  2010-06-18       Impact factor: 5.085

3.  Proteomics identifies multipotent and low oncogenic risk stem cells of the spleen.

Authors:  Francisco Dieguez-Acuña; Shohta Kodama; Yoshiaki Okubo; Ana Cristina Paz; Steven P Gygi; Denise L Faustman
Journal:  Int J Biochem Cell Biol       Date:  2009-12-18       Impact factor: 5.085

Review 4.  Promoting ectopic pancreatic fates: pancreas development and future diabetes therapies.

Authors:  E J Pearl; M E Horb
Journal:  Clin Genet       Date:  2008-09-09       Impact factor: 4.438

5.  Splenocytes seed bone marrow of myeloablated mice: implication for atherosclerosis.

Authors:  Lai Wang; Mingjie Yang; Ana Arias; Lei Song; Fuqiang Li; Fang Tian; Minghui Qin; Ada Yukht; Ian K Williamson; Prediman K Shah; Behrooz G Sharifi
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

6.  The Spleen Is an Ideal Site for Inducing Transplanted Islet Graft Expansion in Mice.

Authors:  Takeshi Itoh; Hitomi Nishinakamura; Kenjiro Kumano; Hiroyuki Takahashi; Shohta Kodama
Journal:  PLoS One       Date:  2017-01-30       Impact factor: 3.240

Review 7.  The Spleen as an Optimal Site for Islet Transplantation and a Source of Mesenchymal Stem Cells.

Authors:  Naoaki Sakata; Gumpei Yoshimatsu; Shohta Kodama
Journal:  Int J Mol Sci       Date:  2018-05-07       Impact factor: 5.923

Review 8.  Immune-Protective Formulations and Process Strategies for Improved Survival and Function of Transplanted Islets.

Authors:  Yannan Shi; Ying-Zheng Zhao; Zhikai Jiang; Zeqing Wang; Qian Wang; Longfa Kou; Qing Yao
Journal:  Front Immunol       Date:  2022-07-12       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.